Autres langues Clearmind Medicine Inc.

Actions

CMND

CA1850534027

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
2,22 ^USD	+30,59 %		+33,73 %	-21,00 %

28/06	Clearmind Medicine Inc. annonce une avancée dans le traitement des comportements excessifs basé sur le MEAI	CI
20/06	Clearmind Medicine obtient les droits mondiaux exclusifs sur des composés psychédéliques innovants pour le traitement du SSPT	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine, Israel 2024 Conference	15/07
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference	12/07
Clearmind Medicine Inc. Announces Advancement in its Proprietary MEAI- Based Binge Behaviors Treatment	28/06
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment	28/06
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment	20/06
Clearmind Medicine Secures Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment	20/06
Clearmind Medicine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	13/06
Clearmind Medicine : Condensed Interim Consolidated Financial Statements Form 6 K	13/06
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink	11/06
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	13/05
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10/05
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10/05
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07/05
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07/05
Clearmind Applies to Cease Being a Reporting Issuer in Canada	30/04
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	17/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine CEO Issues Letter to Shareholders	09/04
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression	27/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Clearmind Medicine Inc.

Actions

CMND

CA1850534027

Autres langues

Filtres